Dossier assessment
Onasemnogene abeparvovec (spinal muscular atrophy with >= 4 copies of the SMN2 gene and SMA Type 2, Type 3, Type 4 or of undefined type, >= 2 years) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Onasemnogene abeparvovec (spinal muscular atrophy with >= 4 copies of the SMN2 gene and SMA Type 2, Type 3, Type 4 or of undefined type, >= 2 years) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Onasemnogene abeparvovec (spinal muscular atrophy with >= 4 copies of the SMN2 gene and SMA Type 2, Type 3, Type 4 or of undefined type, >= 2 years) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Patients aged 2 years and older with 5q spinal muscular atrophy (SMA) with ≥4 copies of the survival motor neuron 2 gene and with SMA type 2, type 3, type 4 or without a defined type
Added benefit not proven
Project details
- Project no.
- A26-99
- Commission
- Commission awarded on 31.07.2026 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Muscles, bones and joints
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A26-99
Connected Projects
-
Dossier assessment
Onasemnogene abeparvovec (spinal muscular atrophy) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed